A Pharmacovigilance Study of the Association Between Proton Pump Inhibitors and Tumor Adverse Events Based on the FDA Adverse Event Reporting System Database

Overview

Journal Front Pharmacol

Date 2025 Jan 3

PMID 39749203

Authors

Ya-Jun Zhang

Dan-Dan Duan

Qian-Yu Tian

Cai-E Wang

Shu-Xun Wei

Affiliations

Soon will be listed here.

Abstract

Background: Proton pump inhibitors (PPIs) are effective treatments for acid-related disorders but may pose tumor risks with long-term use. Current research on PPI-associated tumor adverse events (TAEs) is limited and inconclusive. This study aims to comprehensively analyze the relationship between PPIs and TAEs.

Methods: We analyzed PPI adverse reaction reports from the FDA Adverse Event Reporting System (FAERS) database spanning from 2004 to 2024, focusing on five commonly used PPIs: esomeprazole, pantoprazole, lansoprazole, omeprazole, and rabeprazole. We conducted a disproportionality analysis utilizing the Reporting Odds Ratio (ROR) to identify potential TAEs associated with PPIs. We conducted univariate logistic regression analysis to explore the influencing factors.

Results: A total of 3,133 TAEs were identified, representing 2.36% of all PPI-related adverse events (AEs). The most common TAEs were gastric cancer (19.05%) and malignant neoplasm (7.23%). Disproportionality analysis revealed ten significant TAEs associated with PPIs, including gastric adenocarcinoma and renal cell carcinoma. The median age of those reporting TAEs was 59 (interquartile range [IQR]: 51-70), and 29.70% of them resulted in a fatality. TAEs associated with PPIs were less likely to occur in elderly patients (65-75: OR = 0.91 [0.87-0.95], < 0.001; >75: OR = 0.93 [0.89-0.98], < 0.01).

Conclusion: TAEs constitute a small but significant fraction of PPI-related AEs. This study highlights the need for cautious long-term use of PPIs and further research to understand the underlying mechanisms and risk factors. Clinicians should be aware of the potential tumor risks associated with prolonged PPI treatment.

References

Song S, Guha S, Liu K, Buttar N, Bresalier R . COX-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signalling pathways in Barrett's oesophagus and oesophageal adenocarcinoma. Gut. 2007; 56(11):1512-21. PMC: 2095641. DOI: 10.1136/gut.2007.121244. View

Cheung K, Leung W . Long-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence. Therap Adv Gastroenterol. 2019; 12:1756284819834511. PMC: 6415482. DOI: 10.1177/1756284819834511. View

Fossmark R, Martinsen T, Waldum H . Adverse Effects of Proton Pump Inhibitors-Evidence and Plausibility. Int J Mol Sci. 2019; 20(20). PMC: 6829383. DOI: 10.3390/ijms20205203. View

Lowrance W, Ordonez J, Udaltsova N, Russo P, Go A . CKD and the risk of incident cancer. J Am Soc Nephrol. 2014; 25(10):2327-34. PMC: 4178430. DOI: 10.1681/ASN.2013060604. View

Shin J, Kim N . Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013; 19(1):25-35. PMC: 3548122. DOI: 10.5056/jnm.2013.19.1.25. View

Blair 3rd A, Richardson C, Walsh J, Feldman M . Variable contribution of gastrin to gastric acid secretion after a meal in humans. Gastroenterology. 1987; 92(4):944-9. DOI: 10.1016/0016-5085(87)90968-1. View

Klatte D, Gasparini A, Xu H, de Deco P, Trevisan M, Johansson A . Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease. Gastroenterology. 2017; 153(3):702-710. DOI: 10.1053/j.gastro.2017.05.046. View

Segna D, Brusselaers N, Glaus D, Krupka N, Misselwitz B . Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review with meta-analysis. Therap Adv Gastroenterol. 2021; 14:17562848211051463. PMC: 8586163. DOI: 10.1177/17562848211051463. View

Nandy N, Hanson J, Strickland R, McCarthy D . Solitary Gastric Carcinoid Tumor Associated with Long-Term Use of Omeprazole: A Case Report and Review of the Literature. Dig Dis Sci. 2015; 61(3):708-12. DOI: 10.1007/s10620-015-4014-0. View

10.

Strand D, Kim D, Peura D . 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver. 2016; 11(1):27-37. PMC: 5221858. DOI: 10.5009/gnl15502. View

11.

Bordi C, Bertele A, Davighi M, Pilato F, Carfagna G, Missale G . Clinical and pathological associations of argyrophil cell hyperplasias of the gastric mucosa. Appl Pathol. 1984; 2(5):282-91. View

12.

Nehra A, Alexander J, Loftus C, Nehra V . Proton Pump Inhibitors: Review of Emerging Concerns. Mayo Clin Proc. 2018; 93(2):240-246. DOI: 10.1016/j.mayocp.2017.10.022. View

13.

Cavalcoli F, Zilli A, Conte D, Ciafardini C, Massironi S . Gastric neuroendocrine neoplasms and proton pump inhibitors: fact or coincidence?. Scand J Gastroenterol. 2015; 50(11):1397-403. DOI: 10.3109/00365521.2015.1054426. View

14.

Yao T, Kajiwara M, Kuroiwa S, Iwashita A, Oya M, Kabashima A . Malignant transformation of gastric hyperplastic polyps: alteration of phenotypes, proliferative activity, and p53 expression. Hum Pathol. 2002; 33(10):1016-22. DOI: 10.1053/hupa.2002.126874. View

15.

Malfertheiner P, Kandulski A, Venerito M . Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017; 14(12):697-710. DOI: 10.1038/nrgastro.2017.117. View

16.

. Infection with Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum. 1994; 61:177-240. PMC: 7681529. View

17.

Nishijima K, Miwa K, Miyashita T, Kinami S, Ninomiya I, Fushida S . Impact of the biliary diversion procedure on carcinogenesis in Barrett's esophagus surgically induced by duodenoesophageal reflux in rats. Ann Surg. 2004; 240(1):57-67. PMC: 1356375. DOI: 10.1097/01.sla.0000130850.31178.8c. View

18.

Jianu C, Lange O, Viset T, Qvigstad G, Martinsen T, Fougner R . Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scand J Gastroenterol. 2011; 47(1):64-7. DOI: 10.3109/00365521.2011.627444. View

19.

Guo H, Zhang R, Zhang P, Chen Z, Hua Y, Huang X . Association of proton pump inhibitors with gastric and colorectal cancer risk: A systematic review and meta-analysis. Front Pharmacol. 2023; 14:1129948. PMC: 10060974. DOI: 10.3389/fphar.2023.1129948. View

20.

Rothman K, Lanes S, Sacks S . The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004; 13(8):519-23. DOI: 10.1002/pds.1001. View